NewAmsterdam Pharma(NAMSW)
NARRDEN, Netherlands
PharmaceuticalFocus: Small Molecule
NewAmsterdam Pharma is a life sciences company focused on Small Molecule.
Metabolic DiseasesNeurologyOphthalmologyCardiovascularGastroenterology
Funding Stage
PUBLIC
Total Funding
$196M
Open Jobs
7
Pipeline & Clinical Trials
Obicetrapib 10mg
Healthy VolunteersClinical Trials (1)
NCT06547359A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
Phase 1Obicetrapib
Lipid MetabolismClinical Trials (1)
NCT05972278Investigating the Effect of Obicetrapib on Lipoprotein Metabolism
Phase 1Obicetrapib
Healthy VolunteersClinical Trials (1)
NCT06250205Evaluate the Pharmacokinetics of a Combined Oral Contraceptive (COC) With and Without Obicetrapib
Phase 1Obicetrapib
Healthy VolunteersClinical Trials (1)
NCT06081166A Drug-drug Interaction Study Evaluating the PK Effects of Obicetrapib on Atorvastatin and Rosuvastatin
Phase 1Fixed-Dose Combination
Healthy Volunteer StudyClinical Trials (1)
NCT06050291Investigating the Effect of Food on the Bioavailability of a Fixed Dose Combination of Obicetrapib and Ezetimibe
Phase 1Obicetrapib
Hepatic ImpairmentClinical Trials (1)
NCT06048302PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
Phase 1Obicetrapib 5mg
DyslipidemiasClinical Trials (1)
NCT04770389Randomized Study of Obicetrapib in Combination With Ezetimibe
Phase 2Obicetrapib
DyslipidemiasClinical Trials (1)
NCT05266586Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy
Phase 2Obicetrapib
DyslipidemiaClinical Trials (1)
NCT05421078A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Phase 2Obicetrapib
DyslipidemiasClinical Trials (1)
NCT04753606Randomized Study of Obicetrapib as an Adjunct to Statin Therapy
Phase 2Obicetrapib
Early Alzheimer's DiseaseClinical Trials (1)
NCT05161715Proof-of-concept, Open-label Study in Patients With Early Alzheimer's Disease
Phase 2obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
DyslipidemiasClinical Trials (1)
NCT06496243Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels
Phase 2Obicetrapib 10mg
Antioxidant AbsorptionClinical Trials (1)
NCT06982508Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers
Phase 2Obicetrapib
DyslipidemiasClinical Trials (1)
NCT05425745Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.
Phase 3Combination Therapy
DyslipidemiasClinical Trials (1)
NCT06005597Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies
Phase 3Obicetrapib
Atherosclerotic Cardiovascular DiseaseClinical Trials (1)
NCT05202509Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease
Phase 3obicetrapib 10 mg + ezetimibe 10 mg FDC daily
LipidemiaClinical Trials (1)
NCT07219602A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome
Phase 3Placebo
DyslipidemiasClinical Trials (1)
NCT05142722Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
Phase 3obicetrapib 10 mg + ezetimibe 10 mg FDC daily
LipidemiaClinical Trials (1)
NCT06305559A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
Phase 3Open Jobs (7)
Associate Director, Pharmacovigilance
Remote
23h ago
Clinical Project Manager, Phase I Studies
Remote
Clinical Operations3w ago
Associate Director, Clinical Trial Management
Remote
Clinical Operations1mo ago
Associate Director/Director, Chemical Development (Drug Substance CMC)
Remote
Commercial1mo ago
Director, Clinical Supply
Remote
Clinical Operations1mo ago
Manager, Supply Planning and Logistics
Remote
Supply Chain1mo ago
VP, Strategy
Remote
Business Development1mo ago
Interview Prep Quick Facts
Portfolio: 19 clinical trials
SEC Filings: 2 available
Open Roles: 7 active jobs
Financials (FY2025)
Revenue
$14M86%
R&D Spend
$159M(1131%)84%
Net Income
-$177MCash
$340MHiring Trend
Stable
7
Open Roles
+1
Added
-1
Filled/Removed
Based on last 4 crawl cycles